Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster lunch

1589 - Hematological toxicities following treatment of cancer patients with PARP inhibitors (565P)

Date

18 Nov 2017

Session

Poster lunch

Presenters

Shaimaa Essam-Eldin

Citation

Annals of Oncology (2017) 28 (suppl_10): x177-x182. 10.1093/annonc/mdx668

Authors

S. Essam-Eldin1, E. Salah2, H. Ahmed3, H. Elhalawani3, O. Abdel-Rahman2

Author affiliations

  • 1 Clinical Oncology Department, Ain shams university hospitals, 2205 - Cairo/EG
  • 2 Clinical Oncology Department, Ain Shams University Faculty of Medicine, 11566 - Cairo/EG
  • 3 Cancer Centre, MD Anderson, 73344 - Texas/US
More

Resources

Abstract 1589

Background

A meta-analysis of the risk of hematological adverse events (AEs) associated with the use of PARP inhibitors in patients treated from cancer has been conducted.

Methods

Eligible publications included phase II and III randomized trials of patients treated from cancer with PARP inhibitors, describing events of all-grade and high-grade hematological toxicity which include (anemia, thrombocytopenia, neutropenia, and lymphopenia).

Results

Our search strategy yielded 143 potentially eligible citations from pubmed/MEDLINE, google scholar, clinical trials.gov, ASCO and ESMO meetings library. Ineligible studies were excluded, and a total of 15 RCTs were involved in this analysis, 13 of them were phase 2 trials and only two were phase 3 trials, with a total of 3019 patients. The relative risk was 1.40 [95% confidence interval (CI): 1.26-1.55; p 

Conclusions

Our analysis provided evidence that the use of PARP inhibitors is associated with an increased risk of all-grade and high-grade anemia, thrombocytopenia, neutropenia and lymphopenia compared with chemotherapy or placebo controls.

Clinical trial identification

Legal entity responsible for the study

Omar Abdel-Rahman

Funding

None

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.